Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus

Clinical Therapeutics

Volumn 36, Issue 11, 2014, Pages 1625-1637

  Noe, Adele ^a   Howard, Campbell ^a   Thuren, Tom ^a   Taylor, Ann ^b   Skerjanec, Andrej ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Canakinumab; High sensitivity C reactive protein; Interleukin 1 ; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; METFORMIN; PLACEBO; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; HALF LIFE TIME; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOMARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-1BETA; MALE; METFORMIN; MIDDLE AGED; YOUNG ADULT;

EID: 84911449152     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.08.004     Document Type: Article

References (18)

1. Buse JB, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126.
2. Kaptoge S, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-140.
3. Nissen SE, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
4. Ridker PM, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-28.
5. Morrow DA, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114:281-288.
6. McMurray JJ, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A retrospective analysis. Circulation. 2009;120:2188-2196.
7. Ridker PM, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182.
8. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11:81-89.
9. Chakraborty A, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51:e1-e18.
10. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17:314-321.
11. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605.
12. King DE, Mainous AG 3rd, Buchanan TA, et al. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26:1535-1539.
13. Schnell O, et al. Changes in A1c levels are significantly associated with changes in levels of the cardiovascular risk biomarker hs-CRP: Results from the SteP study. Diabetes Care. 2013;36:2084-2089.
14. Alten R, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R67.
15. Lachmann HJ, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416-2425.
16. So A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:3064-3076.
17. Kuemmerle-Deschner JB, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther. 2011;13:R34.
18. Schlesinger N, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13:R53.